A Pilot Study of LN-144 Immunotherapy in People with Metastatic Uveal Melanoma

Full Title

Patients With Advanced Uveal Melanoma, Undifferentiated Pleomorphic Sarcoma, Dedifferentiated Liposarcoma, or Angiosarcoma

Purpose

Researchers in this study are exploring the feasibility of making an immunotherapy in a laboratory using white blood cells (called lymphocytes or T cells) collected from the tumor of a patient with metastatic uveal melanoma. This is called autologous tumor-infiltrating lymphocyte (TIL) therapy. The TIL therapy being assessed in this study is called LN-144, and it is designed to activate white blood cells to attack the tumor.

The investigators want to see if it is practical to make LN-144 from participants’ T cells and determine if the treatment is safe. LN-144 is given intravenously (by vein).

Contact

For more information about this study and to ask about eligibility, please contact the office of Dr. Alexander Shoushtari at 646-888-4161.